

In the claims:

1. (Currently amended) A method of protecting a solid-state protein from ionizing radiation which comprises combining said protein with a radiation-protecting amount of a ~~methoxysalicylaldehyde~~ 3-methoxysalicylaldehyde prior to exposing said protein to said ionizing radiation.
2. (Canceled)
3. (Previously presented) A method of protecting a solid-state protein from ionizing radiation which comprises combining said protein with radiation-protecting amounts of a methoxysalicylaldehyde and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid prior to exposing said protein to said ionizing radiation.
4. (Previously presented) A method according to claim 3 wherein said methoxysalicylaldehyde is 3-methoxysalicylaldehyde.
5. (Previously presented) A method of protecting a solid-state protein from ionizing radiation which comprises combining said protein with radiation-protecting amounts of a methoxysalicylaldehyde and isopropanol prior to exposing said protein to said ionizing radiation.
6. (Previously presented) A method according to claim 5 wherein said methoxysalicylaldehyde is 3-methoxysalicylaldehyde.
7. (Currently amended) A formulation comprising a solid-state protein and 3-methoxysalicylaldehyde ~~a-methoxysalicylaldehyde~~.
8. (Previously presented) A formulation according to claim 7 wherein said protein is a drug.
9. (Canceled)

10. (Previously presented) A formulation according to claim 7 wherein said methoxysalicylaldehyde comprises at least about 0.1% by weight of said formulation.
11. (Previously presented) A formulation according to claim 10 wherein said methoxysalicylaldehyde comprises from about 2.9% to about 8.0% by weight of said formulation.
12. (Previously presented) A formulation comprising a solid-state protein, a methoxysalicylaldehyde, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.
14. (Previously presented) A formulation according to claim 12 wherein said methoxysalicylaldehyde is 3-methoxysalicylaldehyde.
15. (Previously presented) A formulation according to claim 12 wherein said methoxysalicylaldehyde comprises at least about 0.1% by weight of said formulation, and said 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid comprises at least about 0.1% by weight of said formulation.
16. (Previously presented) A formulation according to claim 15 wherein said methoxysalicylaldehyde comprises from about 2.9% to about 8.0% by weight of said formulation, and said 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid comprises from about 0.1% to about 1.0% by weight of said formulation.
17. (Previously presented) A formulation comprising a solid-state protein, a methoxysalicylaldehyde, and isopropanol.
19. (Previously presented) A formulation according to claim 17 wherein said methoxysalicylaldehyde is 3-methoxysalicylaldehyde.
20. (Previously presented) A formulation according to claim 17 wherein said methoxysalicylaldehyde comprises at least about 0.1% by weight of said formulation, and said isopropanol comprises at least about 0.1% of said formulation.
21. (Previously presented) A formulation according to claim 17 wherein said methoxysalicylaldehyde comprises from about 2.9% to about 8.0% by weight of said

formulation, and said isopropanol acid comprises from about 0.1% to about 4.0% of said formulation.

22. (Previously presented) A composition comprising a methoxysalicylaldehyde and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.

23. (Previously presented) A composition according to claim 22 wherein said methoxysalicylaldehyde is 3-methoxysalicylaldehyde.

24. (Canceled)